Continuous Interscalene Blocks and Rebound Pain

Condition(s) studied

Investigational drug(s) / intervention(s)

Continuous interscalene nerve block: This Interventional Group will receive a continuous interscalene block via a catheter for a duration of 48 hours with ropivacaine 0.2% at a fixed 5 mL/hour rate.

Interscalene Block: This control group will receive a single shot interscalene block with 20 mL of ropivicaine 0.2%.

Study summary

The primary objectives of this present study are to examine whether a continuous interscalene block of a total duration of 48 hours reduces the incidence of rebound pain comparatively to single-shot interscalene block, through the evaluation of the NRS scores at rest and on movement in the postoperative period at 24, 48, 72 and 96 hours as well as the total opioid consumption in the same timeframe for patients undergoing total shoulder arthroplasty.

Rebound pain has been defined in some studies as the "the transition from well-controlled pain (numerical rating scale \[NRS\] ≤3) while the block is working to severe pain (NRS ≥7) within 24 h of block performance."

Eligibility

Primary outcome measure(s)

• incidence of Rebound pain within 96 hours postoperatively — This outcome will be measured within 24 hours of block resolution, for up to 96 hours after the initial block realization.
  The incidence of Rebound Pain, defined as an NRS score of \< 3 during an effective block to an NRS \> 7 within 24 hours of block resolution. This will be analyzed as a binary variable (yes/no)

Trial sites (1)

More University of Calgary trials in Canada

Other trials for the same condition